Intellectual Property Patents

  • WASHINGTON, Jan 18- The U.S. International Trade Commission said on Wednesday it had launched on investigation into whether Fujifilm Holdings Corp was violating patents which Sony Corp holds for certain magnetic tape cartridges.

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of using "anticompetitive" tactics to maintain its monopoly on a key semiconductor used in mobile phones. The FTC, which works with the Justice Department to enforce antitrust law, said that San Diego- based Qualcomm used its dominant...

  • WASHINGTON, Jan 17- The U.S. Federal Trade Commission filed a lawsuit against Qualcomm Inc on Tuesday, accusing the company of antitrust violations in its patent licensing business. The FTC asked the U.S. District Court for the Northern District of California in San Jose to order Qualcomm to cease this and related practices. In February 2015, Qualcomm paid a $975...

  • Jan 17- Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company's patents covering multiple sclerosis drugs including Biogen's flagship drug, Tecfidera. "We believe this agreement will clarify and strengthen our intellectual property for Tecfidera," said Biogen Chief Executive Michel Vounatsos said in a...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schleifer said Amgen had refused a request to...

  • Jan 9- Regeneron Pharmaceuticals Chief Executive Len Schliefer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schliefer said Amgen had refused a request to...

  • Jan 5- Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement. District Judge Sue Robinson in Delaware had ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to...

  • In an October 2014 lawsuit, Amgen had sought to stop Paris- based Sanofi and Tarrytown, New York- based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California- based company's patents related to the...

  • In an October 2014 lawsuit, Amgen had sought to stop Paris- based Sanofi and Tarrytown, New York- based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California- based company's patents related to the...

  • HELSINKI/ BELGRADE, Dec 22- Nokia shares fell by nearly 5 percent on Thursday in Helsinki as analysts warned a legal battle with Apple could delay for years royalty payments that are vital to shoring up the Finnish company's profits. After several years of negotiations trying to reach agreement to cover Apple's use of these patents, we are now taking action to...

  • HELSINKI/ BELGRADE, Dec 22- Nokia shares fell more than 4 percent on Thursday as analysts warned a legal battle with Apple could delay for years royalty payments that are vital to shoring up the Finnish company's profits. But because of the dispute, it could take years to reach a new contract, and royalties will likely come retrospective one-time payments, "said...

  • HELSINKI/ BELGRADE, Dec 22- Nokia shares fell more than 4 percent on Thursday as analysts warned a legal battle with Apple could delay for years royalty payments that are vital to shoring up the Finnish company's profits. But because of the dispute, it could take years to reach a new contract, and royalties will likely come retrospective one-time payments, "said...

  • BELGRADE/ HELSINKI, Dec 21- Nokia Corp said on Wednesday it had filed a number of lawsuits against Apple Inc for violating 32 technology patents, striking back at the iPhone maker's legal action targeting the one-time cellphone industry leader a day earlier. Nokia's lawsuits, filed in courts in Dusseldorf, Mannheim and Munich, Germany, and the U.S. District Court...

  • BELGRADE/ HELSINKI, Dec 21- Nokia Corp said on Wednesday it had filed a number of lawsuits against Apple Inc for violating 32 technology patents, striking back at the iPhone maker's legal action targeting the one-time cellphone industry leader a day earlier. Nokia's lawsuits, filed in courts in Dusseldorf, Mannheim and Munich, Germany, and the U.S. District Court...

  • HELSINKI/ SAN FRANCISCO, Dec 21- Nokia Corp said on Wednesday it had filed a number of lawsuits against Apple Inc for violating 32 technology patents. The lawsuits, filed in courts in Dusseldorf, Mannheim and Munich, Germany and the U.S. District Court for the Eastern District of Texas, cover patents for displays, user interfaces, software, antennas, chipsets and...

  • RPT-NOKIA CORP- FILED A NUMBER OF COMPLAINTS AGAINST APPLE IN GERMANY AND U.S., ALLEGING THAT APPLE PRODUCTS INFRINGE A NUMBER OF NOKIA PATENTS.

  • RPT-NOKIA SUES APPLE IN EUROPE AND THE US FOR INFRINGEMENT OF NOKIA PATENTS.

  • Merck awarded $2.54B in patent suit against Gilead

    The pharmaceutical company wins its hepatitis C drug trial against Gilead Sciences.

  • Harvoni

    Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.